(WNDU) - It’s a taboo topic that nobody talks about. But 1 in 6 Americans suffer with either urinary or bowel incontinence. That’s more than the number of people with Alzheimer’s, diabetes, or breast ...
Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...
Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
NASHVILLE, Tenn. (Ivanhoe Newswire) – It’s a taboo topic that nobody talks about but, almost one in six Americans suffer with urinary or bowel incontinence. That’s more than the number of people with ...
Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary ...
DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...
A successful treatment for bladder incontinence has a new twist that makes it accessible to more people. Bladder incontinence is a problem that impacts about 37 million people. One in six Americans ...
Medtronic plc today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the InterStim™ portfolio’s recharge-free device – and it ...
Dear Dr. Roach: My daughter, who is 50, recently went to a urologist for bladder retention issues. She had several tests performed. My daughter’s doctor told her that the diagnosis is “overactive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback